AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.

BridgeBio Pharma, the US-based Mendelian disease therapy developer backed by insurance group AIG, floated on the Nasdaq Global Market yesterday in an initial public offering sized at approximately $349m.

The offering consisted of 20.5 million shares issued at $17.00 each, above the IPO’s $14 to $16 range. The company also increased the number of shares in the offering from the 15 million figure it had set earlier this week.

The share price gave BridgeBio a valuation of just over $2bn.…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn